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1. ~troduction 
Daunorubicine and adriamycin are antracycline 
antibiotics that inhibit DNA synthesis and have been 
shown to possess potent antitumor activity [l-4]. It 
was demonstrated that such binding is due to two 
types of drug-DNA complex, i.e., an intercalation 
involving a base-pair and chromophore interaction 
and an electrostatic nteraction between the amino 
group of the sugar esidue of the antibiotic and the 
phosphate group of DNA [5]. 
The therapeutic application of daunorubi~ine and 
adriamycin is, however, restricted ue to their toxic 
side effects, such as those manifested in the heart 
muscle and the proliferating bone-marrow cells [6]. 
It was demonstrated that some chemical modifications 
of the drugs could bring about a significant decrease 
in their toxicity [7], and chemically-modified 
adriarnycin has been reported to retain its anti-tumor 
activity [8]. 
We have taken the approach of derivatizing 
daunorubicine by binding peptides of various lengths 
to its amino group and analyzing the modified pro- 
perties of the derivatized rug. The results ummarized 
in this report have shown that the extent of binding 
of daunorubicine derivatives to DNA and their 
biological activity decreased with peptide chain 
length as measured by quenching of fluorescent 
emission and by inhibition of thymidine incorporation 
into drug-treated cells, respectively. Reversing the 
electric charge of daunorubicine or its peptidyl 
derivatives by succinylation strongly reduced their 
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biolo~~al ctivities. When peptides were enzymatic~ly 
cleaved off the derivatized rug, the biological 
activity was significantly regained. 
2. Materials and methods 
2.1. Materials 
Commercial daunorubicin-HCl (DR) was purchased 
from Specia, France. Calf thymus DNA came from 
Wor~ington Biochem. Corp; protease type VI 
@ronase) was from Sigma; concanav~in A (con A) 
from Miles-Yeda; [3H]~y~dine, 5 Ci/mmol from 
Nuclear Research Center, Negev, Israel. N-Carboxy- 
anhydrides (NCA) of the various amino acids, prepared 
by the Fuchs-Farthing method [9], were kindly 
provided by Mr 1. Jacobson of this laboratory. The 
cells used in this report were Wistar male rat 
thymocytes prepared as in [lo] and mouse lymphoma 
cell line EL4 (The Salk Institute, La-Jolla). 
2.2. Preparation of amino acids and peptidyl derivatives 
of da~no~~icine 
The amino acid- and peptidyl-daunorubicine 
derivatives were prepared by coupling NCA of various 
amino acids with the free base of DR. As an example, 
the preparation of N-lysyl-daunorubicine is given 
below. 
N-Lysyl-daunorubicine: DR (10 mg, 18 Mmol) was 
dissolved in 2 ml dry dimethyl-formamide (DMF). 
The solution was shaken with solid Ag,C!Oa and ceri- 
trifuged. The supernatant, containing the free base of 
DR, was reacted with 5.4 mg (20 pmol) of NCA-e- 
t~~uoroacetyl-lys~e dissolved in 0.5 ml DMF. The 
reaction mixture was left at 4°C in the dark for 24 h. 
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The DMF was evaporated inhigh vacuum at room 
temperature. The dry e-TFA-Lys-DR obtained was 
dissolved in 0.1 N NaOH and left in the dark at 4°C 
for 2 h, in order to cleave off the TFA group, y~eid~ng 
N-Lys-DR. Traces of unreacted DR were removed by 
extracting with chloroform the Lys-DR solution 
adjusted to pH 8.5. The other amino acid derivatives 
of DR were obtained similarly. Homopeptides of
DR were obtained by using the appropriate amounts 
of NCA ammo acid. Heteropeptides of DR were 
obtained by first reacting DR with NCA of one amino 
acid and after 24 h the intermediate product was 
reacted with NCA of the second amino acid. Suc- 
cinylation of DR and its peptide derivatives was 
achieved by adding succinic anhydride to a solution 
of the above compounds in sodium bicarbonate 
buffer, at pH 8.0, with vigorous haking. The suc- 
cinylated compounds were separated from excess 
succinic acid by passing through Poropak Q column 
[ 1 I]. Products of the derivatization procedures were 
characterized by thin-layer chromatography on silica 
gel G plates developed in c~oroform:me~anoI: Hz0 
(13:6: 1). The amount of amino acid or peptide 
bound to DR was determined in the amino acid 
analyzer, after total hydrolysis of the derivatives, 
2.3. ~~~di~g to DNA 
To a 2 ml sample of DR or its derivatives at 
5 X 10d6 M in PBS were added 20 ~1 aliquots of 
DNA solution (1 mg/ml). The material was excited at 
485 nm and the fluorescent emission at 580 nm was 
measured in an Aminco-Keirs pectrophosphorimeter, 
according to [12]. 
Rat thymocytes (10’ cells/tube) were incubated 
with DR or with its derivatives for 20 min at 37°C 
and were then washed twice with cold PBS. The cells 
were examined with a Zeiss microscope quipped 
with epifluorescent illumination and filter setting for 
rhodamine fluorescence. 
2.5. Drug activity 
The activity of DR and its derivatives was assayed 
by the inhibition of thymidine incorporation into the 
tested cells. Aliquots of 100 ~1 Eagle’s medium 
supplemented with 5% fetal calf serum containing 
0.5 X IO6 EL4 cells were dispersed in wells of a 
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microtiter plate and various amounts of DR or its 
derivatives were added to the cells for overnight 
incubation in a humidified incubator in 5% COz at 
37*C. [3H]Thymidine was then added (1 ~Ci~well) 
and after incubation for additional 2 h the ceils were 
filtered and their radioactivity counted. DR and its 
derivatives were also used to measure the inhibition 
of thymidine incorporation into mouse thymocytes 
stimulated by the con. A. The cells were cultured in 
Falcon tubes (3 X 1 O6 cells~tube) with 3 @g/ml con A 
for 48 h. The tested drugs were then added for 2 h, 
followed by a 2 h pulse of [3H]thymidine, before 
counting the incorporation of the radioactive 
precursor into acid-insoluble material deposited on 
GF/C fdters. 
3. Results and discussion 
The extent of binding of DR and its derivatives to 
DNA was determined by measuring the quenching of 
fluorescent emission of the tested drugs as in [ 121. As 
can be seen from fig.1, the extent of binding of Ala- 
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Fig.1. Fluorescent emission of daunorubicine and its peptidyl 
derivatives (5 x lOa M) against DNA concentrations: 
excitation, 485 nm; emission, 580 nm. 
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DR is lower than that of the underivatized drug. The 
binding decreases with length of the alanyl chain 
attached to DR. This effect of peptide length on the 
extent of binding is also seen when comparing Lys-DR 
to Lys-Tyr-DR (fig. 1). Lys-DR shows a significantly 
stronger binding to DNA than Ala-DR. This enhanced 
binding is probably due to the additional basic 
e-amino group of the lysine, that could strengthen the 
binding between the amino moiety of DR and the 
phosphate residue of DNA. The enhancing effect of 
the extra amino group on binding to DNA, is further 
demonstrated when comparing the binding of E-TFA- 
Lys-DR to that of Lys-DR. Succinylation of the DR 
or its peptide derivatives results in an almost com- 
plete loss of their ability to bind to DNA. 
The inhibitory activity of DR and its peptide 
derivatives on thymidine incorporation into tumor 
cells is shown in table 1. The activity of the alanyl 
derivatives decreases with the number of alanyl 
residues in the drug, and no inhibitory activity what- 
soever is found with poly(DL-Ala)-DR where the 
number of alanyl residues is over 5. Succinylation of 
DR or of its peptide derivatives strongly reduces the 
inhibitory activity of these drugs on thymidine 
incorporation (table 1). Very similar results not 
shown in table 1 were obtained by testing DR and its 
derivatives on con A-stimulated mouse lymphocytes. 
The inhibitory activity of the peptide derivatives of 
DR on thymidine incorporation correlates in most 
cases with the extent of binding of these drugs to 
DNA as measured by quenching of fluorescent 
emission. Similar observations were made when cells 
were incubated with the drugs and the pattern of 
staining was examined by fluorescent microscopy. 
Whereas DR showed a very strong nuclear staining, 
Leu-DR and Ala-DR stained the nucleus very faintly 
and Ala2-DR or Alas-DR concentrated on the 
periphery of the nucleus without staining the inside. 
All succinylated derivatives tested as well as the long 
chain compound poly(DLAla)-DR, did not show any 
staining of the cells. 
However, a complete correlation was not always 
found between the extent of binding of the derivatized 
DR to DNA as measured by fluorescent emission and 
its inhibitory activity on thymidine incorporation. 
Thus, Lys-DR binds to DNA in vitro much stronger 
than TFA-Lys-DR, although both derivatives inhibit 
thymidine incorporation to the same extent (table 1). 
Table 1 
Inhibition of [ ‘Hlthymidine incorporation by 
daunorubicine and its derivativesa 
Substance % Inhibition of [ ‘Hlthymidine 
incorporation 
Concentration of drug 
lo-’ (M) 5 X 1O-5 (M) 
Daunorubicine 99.7 99.8 
Ala-DR 97 98 
Ala,-DR 82 99 
Ala,-DR 73 94 
DL-Ala,-DR 0 50 
Leu-DR 99.5 99.7 
e-TFA-Lys-DR 98.5 99.7 
Lys-DR 96 99.8 
Lys,-DR 42 99.5 
(Y Sue-Lys-DR 10. 42 
SW-DR 2 32 
Lys-Tyr-DR 30 99.3 
Lys-Phe-DR 99.5 99.9 
Sue Ala, Phe DR 55 73 
Sue Ala, Phe DR + pronase 94.5 99.6 
Sue-Phe,-DR 18 47 
Sue-Phe,-DR + pronase 92 96 
a Based on values of [ ‘Hlthymidine incorporation into EL4 
lymphoma cells as described under section 2. Results are 
averaged from 3 independent experiments 
The fact that the binding of DR derivatives to DNA 
cannot always be correlated with their overall 
inhibitory effect on nuclear metabolism, may be 
explained by the reported binding of DR to the other 
cellular components as phospholipids [ 131 and 
mitochondria [ 141. 
The peptidyl derivatives of DR which are poor 
inhibitors of cell growth, can regain part or most of 
their activity by cleaving off the peptides by 
proteolysis. Thus succinyl-Ala,-Phe-DR which has a 
very low activity is potentiated when treated with 
pronase (0.1 mg/ml for 2 h) (table 1). These 
derivatives might therefore serve as slow releasing 
drugs if they will be reactivated by proteolytic activity 
in their milieu following administration to the body. 
All of the amino acid and peptide derivatives were 
found to be less toxic to C57B1/6 mice than the 
native DR molecule, and the succinylated derivatives 
were not lethal when injected in doses of at least 
500 mg/kg compared with a lethal dose of 5-8 mg/kg 
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recorded for the native DR. Thus the high toxic 
threshold of the derivatives allows their ad~istration 
at much higher doses. In vivo experiments currently 
conducted in our laboratory have indeed confirmed 
that some of the amino acid derivatives of daunorubi- 
tine are far more efficient than the native drug in 
prolonging the life span of tumor-bearing mice, and in 
some cases completely curing them, with reduced 
toxic side effects, (Y.L., B.-A.& in preparation). The 
preparation and study of other amino acid derivatives 
of daunorubicine may provide a new group of chemo- 
therapeutic agents with superior anti-tumor activity. 
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